Every Form 4 that Cingulate Inc. (CING) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CING and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CING filings page.
Cingulate Inc. reported that Chief Executive Officer and director Shane J. Schaffer received two grants of stock options on July 16, 2026. One grant covers 197,650 options and a second covers 97,350 options, each exercisable for common stock at an exercise price of $4.43 per share and expiring on July 16, 2036. The options vest 25% on March 31, 2027, with the remainder vesting in substantially equal monthly installments over the following 36 months. For the 97,350-option grant, even vested options only become exercisable if Cingulate’s NDA for CTx-1301 is approved by the FDA during 2027; if that NDA is not approved during 2027, this option grant, including any vested portion, terminates.
Cingulate Inc. granted EVP & Chief Commercial Officer Bryan Wade Downey two stock option awards covering a total of 100,000 shares of common stock, with an exercise price of $4.43 per share and an expiration date of July 16, 2036.
One option for 67,000 shares vests 25% on March 31, 2027, with the remaining shares vesting in substantially equal monthly installments over the following 36 months. A second option for 33,000 shares follows the same vesting schedule but only becomes exercisable if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027; if that NDA is not approved during 2027, this option, including any vested portion, terminates.
Cingulate Inc. reported that director Lawrence Bryan Jay received a grant of 20,000 Stock Options on 2026-07-16. The options cover 20,000 shares of Common Stock at an exercise price of $4.43 per share, expire on 2036-07-16, and vest on the earlier of the one-year anniversary of grant or the 2027 annual meeting of stockholders. Following this award, Jay holds 20,000 derivative securities directly.
Cingulate Inc. granted stock options to EVP and Chief Medical Officer Matthew Brams on July 16, 2026. He received options to purchase 53,600 and 26,400 shares of common stock at an exercise price of $4.43 per share, expiring on July 16, 2036.
Both option grants vest 25% on March 31, 2027, with the remainder vesting in substantially equal monthly installments over 36 months. The 26,400-share option becomes exercisable only if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027, otherwise the entire option terminates.
Cingulate Inc. director Thomas Jeffrey Hargroves received a grant of 20,000 stock options for Common Stock at an exercise price of $4.43 per share. The options vest on the earlier of the one-year anniversary of the grant date and the date of Cingulate’s 2027 annual meeting of stockholders, and expire on 2036-07-16. Following this grant, he holds 20,000 stock options directly. The grant was not reported under a Rule 10b5-1 trading plan.
Cingulate EVP and CFO Jennifer L. Callahan received two grants totaling 60,000 stock options on July 16, 2026, each with an exercise price of $4.4300 per share and expiring July 16, 2036.
For both grants, 25% vests on March 31, 2027, with the remainder vesting in substantially equal monthly installments over the following 36 months. For 19,800 options, vested options become exercisable only if the NDA for CTx-1301 is approved by the FDA during 2027; if that approval is not obtained in 2027, this grant, including any vested portion, terminates.
Cingulate Inc. director Peter J. Werth received a grant of stock options for 20,000 shares of common stock on July 16, 2026. The options have an exercise price of $4.43 per share and expire on July 16, 2036. They vest on the earlier of the one-year anniversary of the grant date or the date of Cingulate Inc.'s 2027 annual meeting of stockholders, leaving Werth with 20,000 stock options held directly.
Cingulate Inc. EVP and CSO Raul R. Silva received two stock option grants on July 16, 2026. One covers 53,600 shares and the other 26,400 shares of common stock at an exercise price of $4.4300 per share, expiring July 16, 2036. Both vest 25% on March 31, 2027 and then in substantially equal monthly installments over 36 months. The second grant becomes exercisable only if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027; otherwise that option, including any vested portion, terminates.
Cingulate Inc. reported that EVP and CSO Raul R. Silva received a grant of stock options as part of his compensation. The award covers options for 3,885 shares of common stock at an exercise price of $5.47 per share, expiring in 2036. These options were granted pursuant to Dr. Silva's employment agreement and increase his potential equity exposure but do not represent an open-market purchase or sale.
Cingulate Inc. director Thomas Jeffrey Hargroves reported multiple acquisitions of the company’s securities. Through Hargroves Family Investments, LLC, he bought 97,276 shares of common stock at $5.04 per share and 77,821 warrants at $0.10 per warrant on February 13, 2026, tied to a private placement previously described in a Form 8-K. These indirect holdings total 97,468 common shares and 77,821 warrants after the transactions, and he disclaims beneficial ownership beyond his pecuniary interest. On March 9, 2026, he also received a stock option grant for 15,000 shares of common stock at an exercise price of $6.85 per share, vesting 50% six months after grant and the remainder after twelve months, expiring in 2036.
Cingulate Inc. reported that EVP and CSO Raul R. Silva received a grant of stock options covering 3,422 shares of common stock. The options have an exercise price of $6.21 per share, were granted at no purchase cost, and expire on March 31, 2036. The award was made pursuant to Dr. Silva's Employment Agreement, as amended, and reflects equity-based compensation rather than an open-market share purchase or sale.
Cingulate Inc. executive Raul R. Silva, EVP and CSO, received a grant of 4,526 shares of common stock on March 9, 2026 as part of his 2025 bonus under the company’s 2021 Omnibus Equity Incentive Plan. To cover tax obligations on this grant, 1,828 shares were withheld by the company, a non-market, tax-withholding transaction. After these entries, Silva directly holds 4,645 Cingulate common shares.
Cingulate Inc. chief executive Shane J. Schaffer reported a stock-based compensation event. He received 6,862 shares of common stock on 2026-03-09 under Cingulate’s 2021 Omnibus Equity Incentive Plan as part of his 2025 bonus. To cover tax obligations on this grant, 2,959 shares were withheld, which reduced his directly held common stock to 4,076 shares after these transactions.
In addition to these direct holdings, the report lists 10,175 shares of common stock held indirectly through Fountainhead Shrugged, LLC. Schaffer disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.
Cingulate Inc. reported that EVP and CFO Jennifer L. Callahan received a grant of 15,329 shares of common stock on March 9, 2026 as part of her 2025 bonus under the 2021 Omnibus Equity Incentive Plan. Of this grant, 6,427 shares were withheld to cover tax obligations, leaving her with 13,961 shares of common stock held directly after these transactions. The activity reflects a compensation-related stock award combined with tax withholding, not an open-market purchase or sale.
Cingulate Inc. executive Nilay Dahyabhai Patel, EVP, CLO and CCO, received a grant of 5,475 shares of common stock on March 9, 2026. The shares were awarded under Cingulate’s 2021 Omnibus Equity Incentive Plan as part of Patel’s 2025 bonus. To cover related tax obligations, 2,086 shares otherwise issuable were withheld, leaving Patel with 3,389 shares of common stock held directly after these transactions.
Cingulate Inc. reported that EVP and Chief Medical Officer Matthew Brams received a grant of 4,526 shares of common stock on March 9, 2026. The shares were granted under the company’s 2021 Omnibus Equity Incentive Plan as part of his 2025 bonus.
On the same date, 1,025 shares of common stock were withheld to cover his tax obligations related to this grant. After these transactions, Brams directly holds 8,157 shares of common stock. The withholding is a tax payment mechanism, not an open-market sale.
Cingulate Inc.’s SVP and CFO Jennifer L. Callahan reported buying common stock and warrants in a private placement. On February 6, 2026, she purchased 4,864 shares of common stock at $5.04 per share, bringing her direct holdings to 5,059 shares.
She also acquired a warrant to purchase 3,891 shares of common stock for $0.10 per warrant. The warrant becomes exercisable once stockholders approve the private placement under Nasdaq rules, and it expires 36 months after the exercise date.
Cingulate Inc. director Peter J. Werth reported transactions made through Werth Family Investment Associates LLC in connection with the company’s private placement. The LLC purchased 19,455 shares of common stock at $5.04 per share and 15,564 warrants at $0.10 per warrant on February 6, 2026. These common shares bring the LLC’s indirectly held common stock to 117,449 shares, while Werth also holds 92 shares directly. The warrant to purchase 15,564 common shares becomes exercisable only after stockholders approve the private placement, as required by Nasdaq rules, and will expire 36 months after the exercise date.
Cingulate Inc. director and Chief Executive Officer Shane J. Schaffer reported indirect purchases through Fountainhead Shrugged, LLC. On February 6, 2026, the LLC acquired 6,809 shares of common stock at $5.04 per share, bringing its indirectly held common stock to 10,175 shares, while Schaffer also holds 173 shares directly.
On the same date, Fountainhead Shrugged, LLC acquired warrants for 5,447 shares of common stock at $0.10 per warrant. The filing notes these common shares and warrants were obtained in a private placement and that the warrant becomes exercisable once stockholders approve the private placement, with an expiration 36 months after the exercise date.
Cingulate Inc.'s EVP and Chief Medical Officer, Matthew Brams, reported buying company securities in a private placement. On 02/06/2026, he purchased 1,946 shares of common stock at $ 5.04 per share, bringing his directly held common stock to 4,656 shares.
He also acquired a warrant to purchase 1,556 shares of common stock at $ 0.1 per warrant. The warrant becomes exercisable only after stockholders approve the private placement under Nasdaq rules and will expire 36 months after the exercise date.
Cingulate Inc. (CING) reported an insider equity grant. On 09/30/2025, EVP and CSO Raul Silva received a stock option covering 7,334 shares of common stock at an exercise price of $3.92, expiring 09/30/2035. The filing lists transaction code “A,” indicating an award. The option was granted pursuant to Dr. Silva’s Employment Agreement, as amended, and is held directly. Following the grant, 7,334 derivative securities were beneficially owned.
Cingulate Inc. (CING) reported a Form 4 showing its Chief Commercial Officer received a stock option grant to purchase 30,000 shares at an exercise price of $3.8 on 11/03/2025.
The option expires on 11/03/2035 and vests 25% on the one-year anniversary of the grant date, with the remaining shares vesting in substantially equal monthly installments over the following 36 months. Following the grant, 30,000 derivative securities were beneficially owned, held directly.